Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA Methyltransferase>>DC-05

DC-05

Katalog-Nr.GC33148

DC-05 ist ein DNA-Methyltransferase 1 (DNMT1)-Inhibitor mit einem IC50- und einem Kd-Wert von 10,3 μM bzw. 1,09 μM.

Products are for research use only. Not for human use. We do not sell to patients.

DC-05 Chemische Struktur

Cas No.: 890643-16-0

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
272,00 $
Auf Lager
2mg
214,00 $
Auf Lager
5mg
321,00 $
Auf Lager
10mg
459,00 $
Auf Lager
50mg
1.379,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

DC-05 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC50 and a Kd of 10.3 μM and 1.09 μM, respectively.

DC-05 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC50 and a Kd of 10.3 μM and 1.09 μM, respectively. DC-05 shows less potent activities against DNMT3A, DNMT3B, G9a, SUV39H1, MLL1, SET7/9, and PRMT1 (IC50: >200, >200, >150, >150, >150, >150, 37.1 μM). DC-05 (1.25, 2.5, 5, and 10 μM) potently inhibits the proliferation of HCT116 (human colon cancer) and Capan-1 (human pancreatic adenocarcinoma cells) after treatment for 24, 48, and 72 h[1].

[1]. Chen S, et al. Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. J Med Chem. 2014 Nov 13;57(21):9028-41.

Bewertungen

Review for DC-05

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DC-05

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.